This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As pharmaceutical marketers prepare their brands for the future, there are a number of important ways they can learn from digitally-native brands. Analysing the world of digitally-native brands highlights three standout ways in which parts of their approach could be brought to the pharmaceutical world. Be more agile .
A sales representative for a biotech company shared information with oncologists about patients’ attitudes towards treatment options, including the company’s brand. Most physicians are trained in medicine and rely on their experiences to understand patients.
The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharmacompanies.
anti-kickback law that the drugmaker said prevented it from helping heart failure patients, many with low incomes, afford the medicine that costs $225,000 annually. Pharmacompanies have very little control over patients’ prices for their Rxs. A federal appeals court rejected Pfizer’s challenge to a U.S.
PBMs, insurers, pharmacompanies, and hospitals don’t want to give up their profits even if it’s better for the general population. Generic drugs versus branded is also a considerable expense. Will pharma and other healthcare companies partner with disruptive organizations?
This strategic move transformed Actavis into one of the largest pharmacompanies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.
PCD PharmaCompanies are those companies, which provides products to its franchise partners and also distributorship rights and monopoly of marketing for the given geographic area or location. PCD Pharma means Propoganda Distribution. Fossil Remedies presents a list of Top 10 PCD PharmaCompanies in India.
Pfizer and Merck have chosen to designate a select few generic manufacturers to produce cheaper versions of their drugs through the Medicines Patent Pool (MPP). Experts across the board are predicting demand for antiviral drugs will rapidly outpace supply. At this point, one must wonder why the U.S. About those copay cards. spending annually.
Introduction In todays digital-first world, content marketing campaigns are no longer optional for pharmaceutical brands. Imagine content marketing as the heartbeat of a pharmabrands digital presence. So, how can pharmacompanies use content marketing to engage HCPs and patients effectively ? Lets dive in.
This is where partners such as Abacus MedicinePharma Services can really help,” says Simon Estcourt, managing director of Abacus MedicinePharma Services. There are many reasons why a company might prefer to keep commercialisation activities inhouse. De-risking drug launch.
While AbbVie is a poster for everything wrong with pharma, what they have done doesn’t apply to ALL pharmacompanies. A “critical part” of pharmaceutical company AbbVie ‘s success is “face-to-face” interaction, CEO Richard Gonzalez explained in an Aug. 27 email outlining its process for bringing thousands of U.S.
Table of Contents Sr# Headings 1 Introduction: The Pharma Marketing Challenge 2 Building a Winning Pharma Marketing Strategy 3 The Role of Branded Drug Campaigns 4 Innovating for Future Success Introduction: The Pharma Marketing Challenge Marketing pharmaceuticals is no small feat.
The new entity has been developed to service expansion within the prescription medicines market, the trend towards specialist and personalised therapies, and the surge in innovative health technologies. The Sudler brand will be officially retired at an international level.
Talking Medicines has raised £1.1 million) in funding that will be used to develop an artificial intelligence (AI) data platform that can be used by pharmacompanies to gain insights into how patients perceive them. To date Talking Medicines has raised £2.5 million ($1.4
Pharmacompanies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. It’s a dynamic reflection of our purpose. pic.twitter.com/vNqCgWus4w.
Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharmacompany Mayoly Spindler later this year. Ipsen’s specialty pharma business grew almost 13% to €2.6 billion takeover of Clementia Pharma in 2019. billion takeover of Clementia Pharma in 2019.
If pharmacompanies are to live up to their decades-old patient-centric promises then marketing budgets need to move from brands and franchises to omnichannel customer-centric teams, according to one digital transformation leader. Pharmacompanies really need to become patient, but also healthcare professional, centric.
The legacy product now lies outside Bayer’s core areas of cardiology, oncology, haematology, ophthalmology, women’s health and radiopharmaceuticals, and the funds raised from the sale will support the “ongoing transformation of Bayer’s pharma business to focus on key areas of future medical innovation”, said the company.
Given the recent acquisition by EVERSANA, our joint welcome to the event attendees was a natural step in showing our united commitment to provide clients with unmatched support for brands worldwide.
So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). I have worked with and stayed in contact with some R&D people within pharma and they have a different answer. In pharma R&D returns have declined to 1.8 percent—a slight decrease of 0.1
Pharmacompanies are still too focused on profits while people continue to rely on prescription drugs to compensate for unhealthy lifestyles. The headline and byline in a Times editorial said it all “Don’t Fall for Big Pharma’s Savior Act, Heroic work went into the development of the coronavirus vaccines.
The UK’s competition authority has issued its largest ever fine of more than £260 million ($360 million) to several pharmacompanies accused of colluding to hike the price of medicines delivered to the NHS.
In 2025, pharmaceutical trends are redefining how brands connect with healthcare professionals (HCPs), patients, and stakeholders. But what exactly is shaping the future of pharma marketing this year? Brands that fail to provide consistent messaging risk losing trust and engagement.
Experts from top life sciences companies discussed strategies for more effectively engaging oncologists at the Pharma Marketing Network’s 2022 Future Forecast on January 25 th. It’s no longer enough to build brand awareness, according to the panelists. Here are the top three things to know about engaging oncologists in 2022: 1.
Vas Narasimhan, CEO of Novartis, said: “For Novartis, the separation of Sandoz would further support our strategy of building a focused innovative medicinescompany, with depth in five core therapeutic areas, and strength in technology platforms. These highlight the parent company’s focus on innovative and high-value drug development.
In 2019, drugs within the oncology therapeutic area accounted for $143 billion in branded pharmaceutical sales, equalling approximately 20% of all global pharmaceutical sales, according to McKinsey. This has led to a greater push into developing biologic medicine and exploring new ways to discover potential R&D candidates.
The global pandemic has caused pharmacompanies to invest in digital marketing, as healthcare systems across the world adapt to strict lockdown rules. Healthcare companies have been in the vanguard of this change, with an enormous rise in the use of telehealth and all forms of digital communications. This is an increase in 14.2%
By most measures the single largest pharmacompany in the world, US-based Johnson & Johnson (J&J) is also arguably one of the most well-known drugmakers among the general public. . These two acquisitions enabled the company to gain a significant presence in the field of pharmaceutical medicines for the first time.
In this ongoing series , we put a spotlight on contracts between pharmacompanies and contract manufacturing organizations (CMOs). In the same realm, Moderna received a positive bump when the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Spikevax’s use in children aged six to 11.
Pharmacompanies continue to be among the most profitable industries, even outperforming tech companies. The Pharma Spin. Pharma continues to spin the lie about the high development costs of drugs but an analysis tells us the truth. More excess profit comes from the next 100 or 200 brand-name drugs.
But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharmacompanies in the world: AstraZeneca.
Two top pharmacompanies have exited the UK’s voluntary medicines pricing agreement in protest at what the industry has said is a “punitive” system of revenue clawbacks, casting doubt on the future of the scheme in its present form. In December, the ABPI warned that clawback – totalling almost £3.3
The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets around the world and had sales of around $140 million last year.
As the number of people affected by these problems is increasing, there is a high demand for medicines required to treat them. If you are planning to launch Cardiac Diabetic PCD Pharma Franchise, then it is the best time. You need an ISO-confirmed company that has WHO and GMP certification also.
Takeda has joined the ranks of big pharmacompanies jettisoning consumer health businesses in order to concentrate on higher-margin prescription drugs. Takeda Consumer Healthcare sells OTC medicines and other health products with sales of 60 billion yen ($567 million) in fiscal 2019.
New drugs, evolving technologies, and emerging marketing channels are creating fresh opportunities for pharma marketing executives. As more patients turn to digital platforms for information and brands compete in an increasingly crowded market, pharma marketers need to be agile, creative, and tech-savvy to succeed.
Because pharmacists dwell in the world of medicine and see the costs associated with prescriptions daily, they are often much more informed about what a drug will cost compared to a medical doctor or provider’s office. “In talking to pharmacists, they say they want to get people their medications at the right price.”
How do you position your brand as a force for good while addressing public concerns? Think of Big Pharma as a lighthouse: its purpose is to guide and protect, but if the light isn’t clear, it can be misinterpreted. For marketing executives, the goal is simple: give stakeholders the information they need to trust your brand.
You can become part of a big company network as a PCD pharma distributor or a PCD pharma firm. Other than conventional medicines, nowadays, people are making good money by opening franchises in Neuro products, Ayurvedic medicines, Gynec products, etc. Selection of brand. Wide range of products.
Even now, having a CIDO or chief digital officer on the board isn’t ubiquitous among big pharmacompanies, despite the encroachment of big tech firms like Amazon, Google and Apple into the healthcare space. At the same time, the industry is looking to develop digital medicines that improve patient outcomes.
After the war, Pfizer continued to focus on industrial chemicals as much as medicines, producing the citric acid needed for the emerging soft drinks industry, fuelling brands like Coca Cola and Dr Pepper’s expansion in the 1880s. This became their mainstay for many years, laying the basis for their continued growth.
Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Epidiolex (cannabidiol) was the first cannabis-based medicine to be registered by the FDA in 2018, following that with a European approval (as Epidyolex) the following year.
Moreover, the adoption of digital tools like mobile apps and telemedicine platforms is facilitating direct communication between pharmacompanies and end-users. As patients become more digitally savvy, pharmacompanies are investing in creating seamless digital experiences that cater to their needs and preferences.
There’s a new player in the neurology and mental health drugs market after Italy’s Angelini Pharma merged with Switzerland’s Arvelle Therapeutics in a deal worth up to $960 million based around the anti-seizure drug cenobamate. It is a small molecule with a dual action, which stimulates the ?-aminobutyric
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content